Li Y X, Coucke P A, Qian T N, Huang Y R, Gu D Z, Mirimanoff R O, Yu Z H
Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):343-50. doi: 10.1016/s0360-3016(97)00031-x.
The purpose of this study was to analyze prognosis and treatment results for seminoma arising in corrected and uncorrected inguinal cryptorchidism (SCIC and SUIC).
We reviewed 66 patients with inguinal seminomas between June 1958 and December 1991 at the Cancer Hospital and Institute of Chinese Academy of Medical Sciences. Of these patients, 23 had prior orchiopexy and 43 presented with an inguinal form of cryptorchidism. At presentation, 17 of 66 (26%) patients had nodal metastases. This nodal involvement was 30% (7 of 23) for SCIC and 23% (10 of 43) for SUIC, respectively. These numbers are comparable with those in a series of patients treated for scrotal seminoma at our institution (26% vs. 20%). However, 3 of 23 (13%) patients who had prior orchiopexy presented with inguinal nodal metastasis as compared with 0 of 43 patients with SUIC or 4 of 237 patients with scrotal seminoma (p < .05). There were 49 stage I, 5 stage IIA, 8 stage IIB, 3 stage III, and 1 stage IV patients. All patients underwent radical orchiectomy and received further radiotherapy, chemotherapy, or both. Patients with stage I and stage II disease were treated primarily with radiotherapy, whereas patients with stage III and IV disease were treated with chemotherapy.
The overall and disease-free survival at 5 and 10 years was 94% and 92%, 89% and 87%, respectively. The overall 5- and 10-year survival by stage was 100% and 100% for stage I, and 77% and 68% for stage II, respectively (p < .05). There was no significant difference in survival between SUIC and SCIC (93% vs. 96% at 5 years). Four patients developed relapse. Two of these four patients experienced relapse at the inguinal area, due to a marginal miss. Three of four patients with relapse were successfully salvaged, and one died of disease.
Our results indicate that prognosis for inguinal seminoma is excellent and similar to that of scrotal seminoma. Postorchiectomy radiotherapy can be considered as the standard treatment for stage I and IIA inguinal seminoma. We recommend routinely including the para-aortic and ipsilateral pelvic nodes.
本研究旨在分析矫正和未矫正腹股沟隐睾(SCIC和SUIC)中发生的精原细胞瘤的预后和治疗结果。
我们回顾了1958年6月至1991年12月在中国医学科学院肿瘤医院和研究所的66例腹股沟精原细胞瘤患者。在这些患者中,23例曾接受过睾丸固定术,43例表现为腹股沟型隐睾。在就诊时,66例患者中有17例(26%)有淋巴结转移。SCIC的淋巴结受累率为30%(23例中的7例),SUIC为23%(43例中的10例)。这些数字与我们机构一系列阴囊精原细胞瘤患者的数字相当(26%对20%)。然而,23例曾接受过睾丸固定术的患者中有3例(13%)出现腹股沟淋巴结转移,而43例SUIC患者或237例阴囊精原细胞瘤患者中均无此情况(p<0.05)。有49例I期、5例IIA期、8例IIB期、3例III期和1例IV期患者。所有患者均接受了根治性睾丸切除术,并接受了进一步的放疗、化疗或两者兼而有之。I期和II期疾病患者主要接受放疗,而III期和IV期疾病患者接受化疗。
5年和10年的总生存率和无病生存率分别为94%和92%、89%和87%。按分期计算,I期的5年和10年总生存率分别为100%和100%,II期分别为77%和68%(p<0.05)。SUIC和SCIC之间的生存率无显著差异(5年时为93%对96%)。4例患者出现复发。这4例患者中有2例在腹股沟区域复发,原因是切缘遗漏。4例复发患者中有3例成功挽救,1例死于疾病。
我们的结果表明,腹股沟精原细胞瘤的预后良好,与阴囊精原细胞瘤相似。睾丸切除术后放疗可被视为I期和IIA期腹股沟精原细胞瘤的标准治疗方法。我们建议常规包括主动脉旁和同侧盆腔淋巴结。